Table 1 Demographic and clinical characteristics at baseline.

From: Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD

Characteristics

OCT cohort (N = 403 eyes from 381 patients)

Cohort with limited data at Month 24 (N = 413 eyes from 399 patients)

Age at index (patient, years)

 Mean (SD)

77.8 (6.8)

79.6 (6.3)

Gender (patient; n, %)

 Male

141 (37.0%)

142 (35.6%)

 Female

240 (63.0%)

257 (64.4%)

Treatment laterality (patient; n, %)

  

 Unilateral

359 (94.2%)

385 (96.5%)

 Bilateral

22 (5.8%)

14 (3.5%)

VA study eye (ETDRS letters)*

  

 Mean (SD)

58.2 (10.4)

54.6 (11.3)

IRF volume (mm3; n, %)

  

 Mean (SD)

0.14 (0.26)

0.14 (0.25)

SRF volume (mm3; n, %)

  

 Mean (SD)

0.18 (0.28)

0.16 (0.28)

PED volume (mm3; n, %)

  

 Mean (SD)

0.73 (0.96)

0.74 (0.82)

Total fluid volume (mm3; n, %)**

  

 Mean (SD)

1.05 (1.18)

1.04 (0.99)

CSFT (microns)

  

 Mean (SD)

350.1 (109.7)

337.1 (109.3)

  1. *VA at baseline or in the 30-day pre-baseline period. **Total fluid volume is defined as the sum of IRF, SRF and PED fluid volumes.
  2. CSFT central subfield thickness, ETDRS Early Treatment Diabetic Retinopathy Study, IRF intraretinal fluid, OCT optical coherence tomography, PED pigment epithelial detachment, SD standard deviation, SRF subretinal fluid